Morgan Stanley breaks silence on Cerebras with first stock price target after IPO quiet period ends

Cerebras Systems’ post-IPO lull on Wall Street is ending. Morgan Stanley has set what it described as its first stock price target for Cerebras, according to a report carried by TheStreet. The move came after the typical post-initial-public-offering quiet period ended earlier in June, opening the door for more detailed analyst research.

Cerebras began trading on the Nasdaq on May 14, in an IPO that drew strong early market interest. CNBC reported that shares opened at $350, up from an $185 IPO price, and closed up 68% at $311.07 on the debut day.

TheStreet’s report said that for several weeks after the IPO, most analyst coverage was effectively absent or limited. That changed the week that began June 7, when the restrictions on post-IPO publishing eased and a wave of new brokerage notes began.

Morgan Stanley’s new note is notable because it represents the first time the firm has attached a specific target to the stock. The report’s accessible summary did not include the target level, so investors will likely need to wait for the full brokerage note or a reposted figure to confirm the exact number.

While Morgan Stanley adds to the chorus, other firms have already moved to initiate or update coverage on Cerebras. Proactive Investors reported that multiple brokerages initiated coverage around the same period and that the stock rose sharply, citing roughly a 23% jump in connection with the broadened research activity.

Other market commentary also points to a wide range of bullish targets from different banks. Nigeria reported that Wedbush initiated Cerebras stock with an Outperform rating and a $270 price target. Separately, India said UBS initiated coverage with a Buy rating and a $300 price target. These figures illustrate how analysts may be arriving at substantially different assumptions for Cerebras’ near-term scaling and long-term margins.

For Cerebras, increased analyst attention can matter even when it does not change underlying fundamentals immediately. More coverage can improve liquidity, broaden the investor base, and sharpen debate around core questions for AI hardware, such as customer demand for specialized training and inference systems, supply commitments, and whether margins can expand as shipments grow.

Still, important details remain in the analyst notes themselves. The publicly available account of Morgan Stanley’s action, as reflected in TheStreet’s summary, did not spell out the firm’s valuation drivers, revenue or profit assumptions, or the specific catalysts it expects Cerebras to deliver.

What to watch next is the complete set of assumptions behind Morgan Stanley’s target, as well as any follow-on revisions from other brokerages. With the IPO quiet period now past, more firms may be expected to initiate coverage, raising the likelihood of competing forecasts and faster consensus formation around Cerebras’ outlook.